{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:05:40Z","timestamp":1789034740820,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coronary artery bypass graft (CABG) procedures face challenges related to graft failure, driven by factors such as acute thrombosis, neointimal hyperplasia, and atherosclerotic plaque formation. Despite extensive efforts over four decades, the optimal antithrombotic strategy to prevent graft occlusion while minimizing bleeding risks remains uncertain, relying heavily on expert opinions rather than definitive guidelines. To address this uncertainty, we conducted a review of randomized clinical trials and meta-analyses of antithrombotic therapy for patients with CABG. These studies examined various antithrombotic regimens in CABG such as single antiplatelet therapy (aspirin or P2Y<jats:sub>12<\/jats:sub> inhibitors), dual antiplatelet therapy, and anticoagulation therapy. We evaluated outcomes including the patency of grafts, major adverse cardiovascular events, and bleeding complications and also explored future perspectives to enhance long-term outcomes for CABG patients. Early studies established aspirin as a key component of antithrombotic pharmacotherapy after CABG. Subsequent randomized controlled trials focused on adding a P2Y<jats:sub>12<\/jats:sub> inhibitor (such as clopidogrel, ticagrelor, or prasugrel) to aspirin, yielding mixed results. This article aims to inform clinical decision-making and guide the selection of antithrombotic strategies after CABG.<\/jats:p>","DOI":"10.1007\/s11239-023-02940-5","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T01:01:31Z","timestamp":1710550891000},"page":"547-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antithrombotic strategies for preventing graft failure in coronary artery bypass graft"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-9314","authenticated-orcid":false,"given":"Maria Sara","family":"Mauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3878","authenticated-orcid":false,"given":"Simone","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-6401","authenticated-orcid":false,"given":"Carla","family":"Rochira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"8","key":"2940_CR1","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jacc.2018.11.053","volume":"73","author":"T Doenst","year":"2019","unstructured":"Doenst T et al (2019) PCI and CABG for treating stable coronary artery disease: JACC Review topic of the Week. J Am Coll Cardiol 73(8):964\u2013976","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2940_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/0735-1097(96)00206-9","volume":"28","author":"GM Fitzgibbon","year":"1996","unstructured":"Fitzgibbon GM et al (1996) Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28(3):616\u2013626","journal-title":"J Am Coll Cardiol"},{"issue":"Spec 1","key":"2940_CR3","first-page":"32","volume":"37","author":"GA Guida","year":"2022","unstructured":"Guida GA, Angelini GD (2022) Pathophysiology and mechanisms of Saphenous Vein Graft failure. Braz J Cardiovasc Surg 37(Spec 1):32\u201337","journal-title":"Braz J Cardiovasc Surg"},{"issue":"1","key":"2940_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-7120-2-8","volume":"2","author":"GJ Murphy","year":"2004","unstructured":"Murphy GJ, Angelini GD (2004) Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound. Cardiovasc Ultrasound 2(1):8","journal-title":"Cardiovasc Ultrasound"},{"issue":"9","key":"2940_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/01.CIR.97.9.916","volume":"97","author":"JG Motwani","year":"1998","unstructured":"Motwani JG, Topol EJ (1998) Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97(9):916\u2013931","journal-title":"Circulation"},{"issue":"7","key":"2940_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1161\/01.CIR.95.7.1870","volume":"95","author":"Z Yang","year":"1997","unstructured":"Yang Z et al (1997) Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 95(7):1870\u20131876","journal-title":"Circulation"},{"issue":"3","key":"2940_CR7","first-page":"540","volume":"60","author":"I Sopek-Merka\u0161","year":"2022","unstructured":"Sopek-Merka\u0161 I et al (2022) ANTIPLATELET THERAPY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY - UNEVENNESS OF DAILY CLINICAL PRACTICE. Acta Clin Croat 60(3):540\u2013543","journal-title":"Acta Clin Croat"},{"issue":"1","key":"2940_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","volume":"53","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 53(1):34\u201378","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"2940_CR9","doi-asserted-by":"publisher","first-page":"14179","DOI":"10.1038\/s41598-017-13819-w","volume":"7","author":"J Cheung-Flynn","year":"2017","unstructured":"Cheung-Flynn J et al (2017) Limiting Injury during Saphenous Vein Graft Preparation for coronary arterial bypass prevents metabolic decompensation. Sci Rep 7(1):14179","journal-title":"Sci Rep"},{"issue":"1","key":"2940_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jvs.2013.06.004","volume":"60","author":"MJ Osgood","year":"2014","unstructured":"Osgood MJ et al (2014) Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous vein. J Vasc Surg 60(1):202\u2013211","journal-title":"J Vasc Surg"},{"issue":"2","key":"2940_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.coph.2012.01.005","volume":"12","author":"H Weaver","year":"2012","unstructured":"Weaver H et al (2012) Oxidative stress and vein graft failure: a focus on NADH oxidase, nitric oxide and eicosanoids. Curr Opin Pharmacol 12(2):160\u2013165","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"2940_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrcardio.2016.76","volume":"13","author":"MR de Vries","year":"2016","unstructured":"de Vries MR et al (2016) Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol 13(8):451\u2013470","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"2940_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jacc.2010.08.650","volume":"57","author":"TJ Gluckman","year":"2011","unstructured":"Gluckman TJ et al (2011) Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 57(9):1069\u20131077","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2940_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-5223(19)37328-3","volume":"83","author":"MT McEnany","year":"1982","unstructured":"McEnany MT et al (1982) The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 83(1):81\u201389","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2940_CR15","unstructured":"Sharma GV et al (1983) The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation, 68(3 Pt 2): p. Ii218-21."},{"issue":"8389","key":"2940_CR16","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(84)92446-2","volume":"1","author":"RL Lorenz","year":"1984","unstructured":"Lorenz RL et al (1984) Improved aortocoronary bypass patency by low-dose aspirin (100\u00a0mg daily). Effects on platelet aggregation and thromboxane formation. Lancet 1(8389):1261\u20131264","journal-title":"Lancet"},{"issue":"6","key":"2940_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2125.1984.tb02407.x","volume":"17","author":"W Meister","year":"1984","unstructured":"Meister W et al (1984) Low-dose acetylsalicylic acid (100\u00a0mg\/day) after aortocoronary bypass surgery: a placebo-controlled trial. Br J Clin Pharmacol 17(6):703\u2013711","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2940_CR18","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/01.CIR.83.5.1526","volume":"83","author":"TP Gavaghan","year":"1991","unstructured":"Gavaghan TP, Gebski V, Baron DW (1991) Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 83(5):1526\u20131533","journal-title":"Circulation"},{"issue":"6","key":"2940_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/01.CIR.77.6.1324","volume":"77","author":"S Goldman","year":"1988","unstructured":"Goldman S et al (1988) Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77(6):1324\u20131332","journal-title":"Circulation"},{"key":"2940_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.thromres.2016.11.018","volume":"149","author":"T Ivert","year":"2017","unstructured":"Ivert T et al (2017) Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thromb Res 149:64\u201369","journal-title":"Thromb Res"},{"issue":"5","key":"2940_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jth.13667","volume":"15","author":"JS Paikin","year":"2017","unstructured":"Paikin JS et al (2017) Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. J Thromb Haemost 15(5):889\u2013896","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2940_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/jth.12832","volume":"13","author":"JS Paikin","year":"2015","unstructured":"Paikin JS et al (2015) Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. J Thromb Haemost 13(3):448\u2013456","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2940_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0022-5223(94)70392-2","volume":"107","author":"SM Rajah","year":"1994","unstructured":"Rajah SM et al (1994) Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 107(4):1146\u20131153","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"2940_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/01.CIR.87.2.659","volume":"87","author":"V Fuster","year":"1993","unstructured":"Fuster V et al (1993) Aspirin as a therapeutic agent in cardiovascular disease. Special writing Group. Circulation 87(2):659\u2013675","journal-title":"Circulation"},{"issue":"17","key":"2940_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa020798","volume":"347","author":"DT Mangano","year":"2002","unstructured":"Mangano DT (2002) Aspirin and mortality from coronary bypass surgery. N Engl J Med 347(17):1309\u20131317","journal-title":"N Engl J Med"},{"issue":"18","key":"2940_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.117.027597","volume":"136","author":"M Gaudino","year":"2017","unstructured":"Gaudino M et al (2017) Mechanisms, consequences, and Prevention of Coronary Graft failure. Circulation 136(18):1749\u20131764","journal-title":"Circulation"},{"issue":"6","key":"2940_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1510\/icvts.2009.229542","volume":"10","author":"HC Arazi","year":"2010","unstructured":"Arazi HC et al (2010) Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery\u2606\u2606\u2606. Interact Cardiovasc Thorac Surg 10(6):863\u2013867","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2940_CR28","doi-asserted-by":"crossref","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet, (1996) 348(9038): p. 1329\u20131339","DOI":"10.1016\/S0140-6736(96)09457-3"},{"issue":"3","key":"2940_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.103.3.363","volume":"103","author":"DL Bhatt","year":"2001","unstructured":"Bhatt DL et al (2001) Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103(3):363\u2013368","journal-title":"Circulation"},{"issue":"5","key":"2940_CR30","first-page":"1417","volume":"82","author":"JL David","year":"1999","unstructured":"David JL, Limet R (1999) Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. Thromb Haemost 82(5):1417\u20131421","journal-title":"Thromb Haemost"},{"issue":"3","key":"2940_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jtcvs.2004.03.007","volume":"128","author":"E Lim","year":"2004","unstructured":"Lim E et al (2004) Clopidogrel did not inhibit platelet function early after coronary bypass surgery: a prospective randomized trial. J Thorac Cardiovasc Surg 128(3):432\u2013435","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"29","key":"2940_CR32","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","volume":"40","author":"H Schunkert","year":"2019","unstructured":"Schunkert H et al (2019) Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J 40(29):2432\u20132440","journal-title":"Eur Heart J"},{"issue":"3","key":"2940_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/jocs.16189","volume":"37","author":"A Kulik","year":"2022","unstructured":"Kulik A et al (2022) Ticagrelor versus aspirin and vein graft patency after coronary bypass: a randomized trial. J Card Surg 37(3):563\u2013570","journal-title":"J Card Surg"},{"issue":"7","key":"2940_CR34","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/jocs.16492","volume":"37","author":"A Kulik","year":"2022","unstructured":"Kulik A et al (2022) Ticagrelor versus aspirin 2 years after coronary bypass: observational analysis from the TARGET trial. J Card Surg 37(7):1969\u20131977","journal-title":"J Card Surg"},{"issue":"20","key":"2940_CR35","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2010.03.104","volume":"56","author":"G Gao","year":"2010","unstructured":"Gao G et al (2010) Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 56(20):1639\u20131643","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2940_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/imi.0b013e3181bbc754","volume":"4","author":"E Mujanovic","year":"2009","unstructured":"Mujanovic E et al (2009) The effect of combined clopidogrel and aspirin therapy after off-pump coronary surgery: a pilot study. Innovations (Phila) 4(5):265\u2013268","journal-title":"Innovations (Phila)"},{"issue":"23","key":"2940_CR37","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/heartjnl-2012-302449","volume":"98","author":"VA Mannacio","year":"2012","unstructured":"Mannacio VA et al (2012) Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of coronary arteRY bypaSS occlusion after off-pump procedures) randomised study. Heart 98(23):1710\u20131715","journal-title":"Heart"},{"issue":"3","key":"2940_CR38","doi-asserted-by":"publisher","first-page":"E152","DOI":"10.1532\/HSF98.20071196","volume":"11","author":"I Kayacioglu","year":"2008","unstructured":"Kayacioglu I et al (2008) The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum 11(3):E152\u2013E157","journal-title":"Heart Surg Forum"},{"issue":"6","key":"2940_CR39","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.ahj.2010.07.035","volume":"160","author":"JC Sun","year":"2010","unstructured":"Sun JC et al (2010) Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting study. Am Heart J 160(6):1178\u20131184","journal-title":"Am Heart J"},{"issue":"25","key":"2940_CR40","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1161\/CIRCULATIONAHA.110.978007","volume":"122","author":"A Kulik","year":"2010","unstructured":"Kulik A et al (2010) Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circulation 122(25):2680\u20132687","journal-title":"Circulation"},{"issue":"8","key":"2940_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/09537104.2017.1280147","volume":"28","author":"S Rafiq","year":"2017","unstructured":"Rafiq S et al (2017) Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets 28(8):786\u2013793","journal-title":"Platelets"},{"issue":"1","key":"2940_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.athoracsur.2013.08.058","volume":"97","author":"R Ebrahimi","year":"2014","unstructured":"Ebrahimi R et al (2014) Effect of clopidogrel use post coronary artery bypass surgery on graft patency. Ann Thorac Surg 97(1):15\u201321","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"2940_CR43","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","volume":"110","author":"KA Fox","year":"2004","unstructured":"Fox KA et al (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) Trial. Circulation 110(10):1202\u20131208","journal-title":"Circulation"},{"issue":"11","key":"2940_CR44","doi-asserted-by":"publisher","first-page":"e020413","DOI":"10.1161\/JAHA.120.020413","volume":"10","author":"J Qu","year":"2021","unstructured":"Qu J et al (2021) Dual antiplatelet therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in patients undergoing coronary artery bypass graft surgery. J Am Heart Assoc 10(11):e020413","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2940_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.amjcard.2017.12.010","volume":"121","author":"R Ebrahimi","year":"2018","unstructured":"Ebrahimi R et al (2018) Comparison of outcomes and costs Associated with aspirin\u2009\u00b1\u2009Clopidogrel after coronary artery bypass grafting. Am J Cardiol 121(6):709\u2013714","journal-title":"Am J Cardiol"},{"issue":"10","key":"2940_CR46","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.amjcard.2014.02.024","volume":"113","author":"H Gasparovic","year":"2014","unstructured":"Gasparovic H et al (2014) Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. Am J Cardiol 113(10):1660\u20131667","journal-title":"Am J Cardiol"},{"issue":"2","key":"2940_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jacc.2016.10.043","volume":"69","author":"S van Diepen","year":"2017","unstructured":"van Diepen S et al (2017) Dual antiplatelet therapy Versus Aspirin Monotherapy in Diabetics with Multivessel Disease undergoing CABG: FREEDOM insights. J Am Coll Cardiol 69(2):119\u2013127","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2940_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/heartjnl-2015-308691","volume":"102","author":"J Saw","year":"2016","unstructured":"Saw J et al (2016) Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. Heart 102(10):763\u2013769","journal-title":"Heart"},{"issue":"16","key":"2940_CR49","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2018.3197","volume":"319","author":"Q Zhao","year":"2018","unstructured":"Zhao Q et al (2018) Effect of Ticagrelor Plus aspirin, Ticagrelor alone, or aspirin alone on Saphenous Vein Graft Patency 1 year after coronary artery bypass grafting: a Randomized Clinical Trial. JAMA 319(16):1677\u20131686","journal-title":"JAMA"},{"issue":"19","key":"2940_CR50","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1161\/CIRCULATIONAHA.120.050749","volume":"142","author":"LM Willemsen","year":"2020","unstructured":"Willemsen LM et al (2020) Effect of adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in patients undergoing coronary artery bypass grafting (POPular CABG): a Randomized, Double-Blind, placebo-controlled trial. Circulation 142(19):1799\u20131807","journal-title":"Circulation"},{"issue":"6","key":"2940_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jama.2022.11966","volume":"328","author":"S Sandner","year":"2022","unstructured":"Sandner S et al (2022) Association of Dual Antiplatelet Therapy with Ticagrelor with Vein Graft failure after coronary artery bypass graft surgery: a systematic review and Meta-analysis. JAMA 328(6):554\u2013562","journal-title":"JAMA"},{"issue":"3","key":"2940_CR52","first-page":"520","volume":"57","author":"M von Scheidt","year":"2020","unstructured":"von Scheidt M et al (2020) Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 57(3):520\u2013528","journal-title":"Eur J Cardiothorac Surg"},{"issue":"12","key":"2940_CR53","first-page":"E305","volume":"32","author":"BA Danek","year":"2020","unstructured":"Danek BA et al (2020) A Randomized Controlled Trial of Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis. J Invasive Cardiol 32(12):E305\u2013E312","journal-title":"J Invasive Cardiol"},{"issue":"3","key":"2940_CR54","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/icvts\/ivaa115","volume":"31","author":"S Gupta","year":"2020","unstructured":"Gupta S et al (2020) Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. Interact Cardiovasc Thorac Surg 31(3):354\u2013363","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2940_CR55","doi-asserted-by":"publisher","first-page":"l5476","DOI":"10.1136\/bmj.l5476","volume":"367","author":"K Solo","year":"2019","unstructured":"Solo K et al (2019) Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ 367:l5476","journal-title":"BMJ"},{"issue":"6","key":"2940_CR56","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","volume":"57","author":"C Held","year":"2011","unstructured":"Held C et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 57(6):672\u2013684","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2940_CR57","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtcvs.2018.10.032","volume":"158","author":"F Xu","year":"2019","unstructured":"Xu F et al (2019) Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: a single-center randomized controlled trial. J Thorac Cardiovasc Surg 158(2):430\u2013437e4","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2940_CR58","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.21037\/jtd-20-3407","volume":"13","author":"Y Tang","year":"2021","unstructured":"Tang Y et al (2021) Aspirin plus ticagrelor or clopidogrel on graft patency one year after coronary bypass grafting: a single-center, randomized, controlled trial. J Thorac Dis 13(3):1697\u20131705","journal-title":"J Thorac Dis"},{"issue":"5","key":"2940_CR59","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","volume":"60","author":"PK Smith","year":"2012","unstructured":"Smith PK et al (2012) Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 60(5):388\u2013396","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2940_CR60","first-page":"466","volume":"50","author":"C Bai","year":"2022","unstructured":"Bai C et al (2022) [A randomized controlled trial of indobufen versus aspirin in the prevention of bridging restenosis after coronary artery bypass grafting]. Zhonghua Xin xue guan bing za zhi 50(5):466\u2013470","journal-title":"Zhonghua Xin xue guan bing za zhi"},{"key":"2940_CR61","doi-asserted-by":"crossref","unstructured":"Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg, (1993) 7(4): p. 169\u2013180","DOI":"10.1016\/1010-7940(93)90155-5"},{"issue":"8866","key":"2940_CR62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0140-6736(93)91815-4","volume":"342","author":"J van der Meer","year":"1993","unstructured":"van der Meer J et al (1993) Prevention of one-year vein-graft occlusion after aortocoronary- bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The Lancet 342(8866):257\u2013264","journal-title":"The Lancet"},{"key":"2940_CR63","doi-asserted-by":"crossref","unstructured":"The effect of aggressive lowering of Low-Density Lipoprotein Cholesterol Levels and low-dose anticoagulation on obstructive changes in Saphenous-Vein coronary-artery bypass grafts. N Engl J Med, (1997) 336(3): p. 153\u2013163","DOI":"10.1056\/NEJM199701163360301"},{"issue":"2","key":"2940_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/01.CIR.102.2.157","volume":"102","author":"GL Knatterud","year":"2000","unstructured":"Knatterud GL et al (2000) Long-Term effects on clinical outcomes of aggressive lowering of Low-Density Lipoprotein Cholesterol Levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 102(2):157\u2013165","journal-title":"Circulation"},{"issue":"4","key":"2940_CR65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","volume":"17","author":"D Capodanno","year":"2020","unstructured":"Capodanno D et al (2020) Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Reviews Cardiol 17(4):242\u2013257","journal-title":"Nat Reviews Cardiol"},{"issue":"1","key":"2940_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366(1):9\u201319","journal-title":"N Engl J Med"},{"issue":"8","key":"2940_CR67","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"2","key":"2940_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacc.2018.10.048","volume":"73","author":"A Lamy","year":"2019","unstructured":"Lamy A et al (2019) Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. J Am Coll Cardiol 73(2):121\u2013130","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2940_CR69","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11239-011-0613-6","volume":"32","author":"JC Sun","year":"2011","unstructured":"Sun JC et al (2011) Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. J Thromb Thrombolysis 32(3):378\u2013385","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2940_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jocs.12074","volume":"28","author":"SV Deo","year":"2013","unstructured":"Deo SV et al (2013) Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg 28(2):109\u2013116","journal-title":"J Card Surg"},{"issue":"10","key":"2940_CR71","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2013.07.017","volume":"112","author":"AG Nocerino","year":"2013","unstructured":"Nocerino AG, Achenbach S, Taylor AJ (2013) Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol 112(10):1576\u20131579","journal-title":"Am J Cardiol"},{"issue":"2","key":"2940_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ et al (2019) 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J 40(2):87\u2013165","journal-title":"Eur Heart J"},{"issue":"1","key":"2940_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ejcts\/ezx314","volume":"53","author":"M Sousa-Uva","year":"2018","unstructured":"Sousa-Uva M et al (2018) 2017 EACTS guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg 53(1):5\u201333","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10","key":"2940_CR74","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","volume":"131","author":"A Kulik","year":"2015","unstructured":"Kulik A et al (2015) Secondary Prevention after coronary artery bypass graft surgery. Circulation 131(10):927\u2013964","journal-title":"Circulation"},{"key":"2940_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.01.011","volume":"259","author":"CJ Malm","year":"2023","unstructured":"Malm CJ et al (2023) Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial. Am Heart J 259:1\u20138","journal-title":"Am Heart J"},{"issue":"6","key":"2940_CR76","doi-asserted-by":"publisher","first-page":"e070823","DOI":"10.1136\/bmjopen-2022-070823","volume":"13","author":"X Yuan","year":"2023","unstructured":"Yuan X et al (2023) Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOP-CABG trial study. BMJ Open 13(6):e070823","journal-title":"BMJ Open"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02940-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:12:21Z","timestamp":1713445941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02940-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02940-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"25 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DC declares speaker\u2019s honoraria from Chiesi, Novo Nordisk, Sanofi and Terumo. All the other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosures"}}]}}